<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00239174</url>
  </required_header>
  <id_info>
    <org_study_id>DRI5029</org_study_id>
    <nct_id>NCT00239174</nct_id>
  </id_info>
  <brief_title>A Multicenter Study to Evaluate the Efficacy and Safety of of Four Doses of SR147778 in Obese Patients</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multi-Center Study Evaluating the Efficacy and Safety of Four Doses of SR147778 in Obese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of SR147778 on weight loss over a period of&#xD;
      24 weeks when prescribed with a hypocaloric diet in obese patients. The secondary objective&#xD;
      is to assess the safety and tolerability of SR147778 and to assess the effect of SR147778 on&#xD;
      several secondary parameters (such as waist, metabolic parameters) over a period of 24 weeks&#xD;
      when prescribed with a hypocaloric diet in obese patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight loss at 6 months.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Waist circumference,lipid parameters,glycemic parameters,metabolic syndrome,blood pressure,adipokines,CRP,IL-6,IL-2,patient satisfaction,food behavior,daily caloric intake, and dietary compliance at 6 months.</measure>
  </secondary_outcome>
  <enrollment type="Actual">394</enrollment>
  <condition>Obesity</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SR147778</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must voluntarily sign the informed consent,&#xD;
&#xD;
          -  Patients must be male or female and aged 18 to 65 years,&#xD;
&#xD;
          -  Patients must be able to follow verbal and written instructions,&#xD;
&#xD;
          -  Female patients of childbearing potential (pre-menopausal women) must have a confirmed&#xD;
             negative urine b-hCG pregnancy test prior to enrollment and Baseline Visit. They must&#xD;
             use an acceptable double method of birth control (e.g., oral or implanted&#xD;
             contraceptive therapy, or IUDs, plus a barrier such as condom, diaphragm or&#xD;
             spermicide) throughout the study, and accept to repeat urine b-hCG pregnancy test at&#xD;
             designated visits,&#xD;
&#xD;
          -  Patients must have a BMI &gt;=30 and &lt;= 40 at screening&#xD;
&#xD;
          -  Patients must have had a stable weight (variation of less than 5 kg during the 90 days&#xD;
             preceding the Screening Visit)&#xD;
&#xD;
          -  Patients must have shown to be compliant to dietary recommendations between the&#xD;
             Screening and the Baseline Visits&#xD;
&#xD;
          -  Patients' physical examination, laboratory evaluations, 12-lead ECG must be within&#xD;
             normal limits (with the exception of abnormalities considered as clinically&#xD;
             insignificant in the opinion of the Investigator and the Center Monitor), or within&#xD;
             predefined limits for hemoglobin (&gt;= 11 g/dL), total cholesterolemia (&lt;= 3 g/L, i.e.&#xD;
             7.7 mmol/L), triglyceridemia (&lt;= 7 g/L, i.e. 7.9 mmol/L), fasting glycemia (&lt;= 1.6&#xD;
             g/L, i.e. 8.9 mmol/L), and hemoglobin A1c (&lt;= 8%).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female patients who are pregnant or lactating,&#xD;
&#xD;
          -  Patients who are considered by the Investigator to be unsuitable candidates for&#xD;
             receipt of an investigational drug,&#xD;
&#xD;
          -  Myocardial infarction within 12 months,&#xD;
&#xD;
          -  Hypertension (SBP &gt; 160 mmHg; DBP &gt; 95 mmHg),&#xD;
&#xD;
          -  Secondary hypertension- Confirmed heart rate &lt; 60 beats/minute,&#xD;
&#xD;
          -  Type 1 diabetes, or treated with insulin&#xD;
&#xD;
          -  History or presence of pancreatitis,&#xD;
&#xD;
          -  History or presence of clinically significant cardiac valve disorder or abnormal&#xD;
             cardiac echography.&#xD;
&#xD;
          -  History or concurrent DSM-IV bulimia or anorexia nervosa,&#xD;
&#xD;
          -  Patients with mental retardation or any clinically significant psychiatric disorder&#xD;
             (including organic mental disorder) other than mild mood or anxiety,&#xD;
&#xD;
          -  History (during the past six months) or concurrent DSM-IV substance abuse or&#xD;
             dependence (excluding nicotine and caffeine as far as patient agrees not to modify&#xD;
             her/his consumption throughout the study),&#xD;
&#xD;
          -  Severe or multiple drug allergies,&#xD;
&#xD;
          -  Any disorder that may interfere with drug absorption, metabolism distribution or&#xD;
             excretion,&#xD;
&#xD;
          -  Presence of any clinically significant gastrointestinal, cardiovascular, hepatic,&#xD;
             renal, hematological, endocrine, dermatological or respiratory disease, or any other&#xD;
             medical condition that might interfere with the evaluation of study medication,&#xD;
&#xD;
          -  Prolonged QTcB: &gt; 450 msec for men and &gt; 470 msec for women.&#xD;
&#xD;
          -  Patients who test positive for any illicit drug included in the urine drug screen&#xD;
             (THC) at the Screening or the Baseline Visit. Patients positive for benzodiazepines&#xD;
             only may be admitted, if prescribed with stable dose regimen.&#xD;
&#xD;
          -  Patients who test positive at the Screening Visit for hepatitis B surface antigen,&#xD;
             hepatitis C antibody, or ALT and/or AST &gt; 2 x upper limit of normal,&#xD;
&#xD;
          -  Hb &lt; 11g/dL, fasting glycemia &gt; 1.6 g/L i.e. 8.9 mmol/L, HbA1c &gt; 8%, total&#xD;
             cholesterolemia &gt; 3 g/L i.e. 7.7 mmol/L, or TG &gt; 7 g/L i.e. 7.9 mmol/L, creatinemia &gt;&#xD;
             150 mmol/l- Patients who have received anti-obesity drugs or other drug(s) or&#xD;
             preparation(s) including herbal for weight reduction within three months of Screening&#xD;
             Visit,&#xD;
&#xD;
          -  Thyroid therapy, except on replacement therapy.&#xD;
&#xD;
          -  Patients using nicotine substitutes or taking bupropion,&#xD;
&#xD;
          -  Treated with antidepressant or neuroleptics drug(s) for more than one week within&#xD;
             three months of Screening Visit,&#xD;
&#xD;
          -  Treated with non selective systemic antihistamines&#xD;
&#xD;
          -  Systemic corticosteroids or inhaled corticosteroids&#xD;
&#xD;
          -  Treated with potent inhibitors of CYP3A4&#xD;
&#xD;
          -  Consuming more than 20 g/day of alcohol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martine Laville, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Edouard Herriot, Endocrinologie-Diabète-Nutrition, 5 Place d'Arsonval, 69437 LYON cedex 03, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>sanofi-aventis Australia &amp; New Zealand administrative office</name>
      <address>
        <city>Macquarie Park</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.sanofi-aventis.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>December 2008</verification_date>
  <study_first_submitted>October 13, 2005</study_first_submitted>
  <study_first_submitted_qc>October 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2005</study_first_posted>
  <last_update_submitted>December 9, 2008</last_update_submitted>
  <last_update_submitted_qc>December 9, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2008</last_update_posted>
  <responsible_party>
    <name_title>ICD Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Surinabant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

